News » MHRA alert » Alert: Tuzulby 20mg, 30mg and 40mg prolonged-release chewable tablets
July 24th 2026
Two batches each of Tuzulby 20mg, 30mg and 40mg prolonged-release chewable tablets (methylphenidate hydrochloride) have incorrect PILs, MHRA has published in an alert.
The affected batches are:
20mg prolonged-release chewable tablets
| Batch No. | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| 77951 | 08/2028 | 30 | 18/12/2025 |
| 79949 | 02/2029 | 30 | 22/06/2026 |
| Batch No. | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| 78001 | 08/2028 | 30 | 18/12/2025 |
| 79961 | 02/2029 | 30 | 22/06/2026 |
40mg prolonged-release chewable tablets
| Batch No. | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| 78011 | 08/2028 | 30 | 18/12/2025 |
| 79974 | 02/2029 | 30 | 22/06/2026 |
Neuraxpharm UK Ltd has informed the MHRA of missing safety information relating to epistaxis (nosebleed). The omitted information concerns addition of epistaxis (frequency not known) as an adverse reaction within the Summary of Product Characteristics and Patient Information Leaflet.
A corrected version of the Patient Information Leaflet, and SPCs for the 20mg, 30mg, and 40mg products are available online. Hard copies of the updated PIL are also available
Patients should continue to take Tuzulby prolonged release chewable tablets as prescribed.
For all medical information enquiries and information on this product, please email Medinfo-uk@neuraxpharm.com, or telephone +44 (0) 330 128 0919. For stock control enquiries please email info-uk@neuraxpharm.com, or telephone +44 (0) 118 211 4039.
